ABSTRACT
Background Although most neonates with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections have mild disease, the impact on neurodevelopmental outcomes is unknown. This study aimed to assess 18-month neurodevelopmental outcomes of neonates infected with SARS-CoV-2 infection.
Methods We conducted a prospective cohort study of neonates diagnosed with SARS-CoV-2 infection between June 2020–August 2020 through nasopharyngeal coronavirus disease 2019 (COVID-19) PCR testing. A total of 58 neonates were identified from the Kuwait national COVID-19 registry and were enrolled. Historical controls were selected from the neonatal follow-up registry and matched 2:1 based on sex and gestational age. At 18 months of age, neurodevelopmental outcomes were assessed using Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-III) by two trained assessors.
Results A total of 40 children were diagnosed with SARS-CoV-2 infection and included in the final analysis. The median age at infection was 18 days (range: 10-26 days). Eighteen (45%) were asymptomatic, 15 (37.5%) had a sepsis-like presentation, 5 (12.5%) had respiratory distress and 2 (5%) had a multisystem inflammatory syndrome in children (MIS-C)-like presentation. At 18 months follow up, only one child had severe developmental delay, and one child had a language delay. BSID-III outcomes did not significantly differ between the SARS-CoV-2 infected group and the control group.
Conclusions There is no difference in neurodevelopmental outcomes in children infected with SARS-CoV-2 infection at 18 months compared to controls, although longer neurodevelopmental follow-up studies are required.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB by the Ministry of Health of Kuwait gave approval for this work number 2021-1638.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of interest: None.
Ethical Approval/Informed Consent: Ethics approval was granted by the Ministry of Health of Kuwait (approval number 2021-1638). Verbal informed consent obtained from the child’s parents prior to conducting the study.
Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- BSID-III
- Bayley Scales of Infant and Toddler Development-3rd Edition
- COVID-19
- coronavirus disease 2019
- GMFCS
- Gross Motor Function Classification System
- IQR
- interquartile range
- MIS-C
- multisystem inflammatory syndrome in children
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus-2
- SD
- standard deviation